Document:USA FDA Guidance for Industry - Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency Mar-2020: Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
gxplex>GxPlexBot Import from GxPlex Excel |
(No difference)
| |
Revision as of 14:27, 29 June 2026
| Document information | |
|---|---|
| Reference | USA FDA Guidance for Industry -
Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency Mar-2020 |
| Validity area | USA |
| Scope(s) | G |
| Document name | FDA Guidance for Industry -
Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency |
| Version / Revision | Mar-2020 |
| Status | Superseded / Invalid |
| Document type | Official recommendation |
| Language(s) | EN |
| Description | Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency
Guidance for Industry, Investigators, and Institutional Review Boards |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
References
| Reference | Scope | Document part | Language | Preview |
|---|---|---|---|---|
| Reference:USA FDA Guidance for Industry - Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency Mar-2020 Q15 | G | Q15 | EN | Q15. I am a study monitor and am unable to conduct on-site monitoring visits due to the COVID-19 public health emergency. May I remotely perform the site monitoring visit? What recommendations does ... |
